Search results
Results from the WOW.Com Content Network
Rubella vaccine is a vaccine used to prevent rubella. [1] Effectiveness begins about two weeks after a single dose and around 95% of people become immune. Countries with high rates of immunization no longer see cases of rubella or congenital rubella syndrome .
Four out of six WHO regions have goals to eliminate rubella, with the WHO recommending using existing measles programmes for vaccination with combined vaccines such as the MMR vaccine. The number of reported cases dropped from 670,000 in the year 2000 to below 15,000 in 2018, and the global coverage of rubella vaccination was estimated at 69% ...
Rubella virus, scientific name Rubivirus rubellae, is a member of the genus Rubivirus and belongs to the family of Matonaviridae, whose members commonly have a genome of single-stranded RNA of positive polarity which is enclosed by an icosahedral capsid.
Rubella occurs worldwide. The virus tends to peak during the spring in countries with temperate climates. Before the vaccine against rubella was introduced in 1969, widespread outbreaks usually occurred every 6–9 years in the United States and 3–5 years in Europe, mostly affecting children in the 5–9 year old age group. [37]
1975: Rubella vaccination for 11–13 years old girls and seronegative mothers. 1982: Two doses of MMR vaccination at 14–18 months and 6 years of age were introduced in the national childhood vaccination programme. 2009: Rotavirus vaccine introduced at 2, 3 and 5 months to all children (September 2009)
A variant of the rustrela virus-- related to the wider-known rubella virus which causes a skin rash in humans -- called RusV was discovered in a female mountain lion in Douglas County, Colorado ...
This is an accepted version of this page This is the latest accepted revision, reviewed on 20 December 2024. Combined vaccine against measles, mumps, and rubella Pharmaceutical compound MMR vaccine MMR vaccine Combination of Measles vaccine Vaccine Mumps vaccine Vaccine Rubella vaccine Vaccine Clinical data Trade names M-M-R II, Priorix, Tresivac, others Other names MPR vaccine AHFS / Drugs ...
Jeremy Farrar, co-author of the concept of CEPI, and board member. The concept for CEPI was outlined in a July 2015 paper in The New England Journal of Medicine, titled "Establishing a Global Vaccine-Development Fund", co-authored by British medical researcher Jeremy Farrar (a director of Wellcome Trust), American physician Stanley A. Plotkin (co-discoverer of the Rubella vaccine), and ...